版本:
中国

BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo

Sept 20 Bristol-Myers Squibb Co :

* European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer

* Validation of application confirms submission is complete and begins EMA's centralized review process Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐